Maxygen And Astellas Form Joint Venture, Combining Cash And Staff
This article was originally published in The Pink Sheet Daily
Executive Summary
Three senior execs will depart in a deal that could result in a staged acquisition of the J/V by the Japanese pharma.
You may also be interested in...
Scene And Heard At BIO - From The IN VIVO Blog
Take our molecules...please! And "Pim's" cup runneth over, from BIO's annual meeting in Chicago.
Scene And Heard At BIO - From The IN VIVO Blog
Take our molecules...please! And "Pim's" cup runneth over, from BIO's annual meeting in Chicago.
Astellas-Maxygen Joint Venture Highlights Japan's Creative Alliances - BIO Asia Conference
TOKYO - Astellas, like most top-tier Japanese pharmaceutical companies, has been aggressive in its out-licensing in the past year, and its 2009 joint venture with Maxygen highlights how Japanese companies are using creative deals to stay competitive